Baptist Regional Cancer Center at Baptist Riverside — Knoxville, Tennessee

Baptist Regional Cancer Center at Baptist Riverside is a clinical research site located in Knoxville, Tennessee, United States 37901.

Crixeo Clinical Trials Trust Score: 15/100 (FAILING). This profile has not yet been claimed by the site owner.

Baptist Regional Cancer Center at Baptist Riverside has participated in 5 clinical trials.

Therapeutic areas: Head and Neck Cancer, Multiple Myeloma, Plasma Cell Neoplasm.

Sponsors: Vanderbilt-Ingram Cancer Center, University of Tennessee.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Knoxville

Browse all research sites in Tennessee · View every site in Knoxville

Sponsor Feasibility Report

Trust Score: 15/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Baptist Regional Cancer Center at Baptist Riverside?

Baptist Regional Cancer Center at Baptist Riverside has a Crixeo Trust Score of 15/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Baptist Regional Cancer Center at Baptist Riverside conducted?

Baptist Regional Cancer Center at Baptist Riverside has 5 clinical trials on record. Their work covers Head and Neck Cancer, Multiple Myeloma, Plasma Cell Neoplasm.

Is Baptist Regional Cancer Center at Baptist Riverside accredited by Crixeo Clinical Trials?

Baptist Regional Cancer Center at Baptist Riverside has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Baptist Regional Cancer Center at Baptist Riverside?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.